PT - JOURNAL ARTICLE AU - Nora Drick AU - Jan Fuge AU - Benjamin Seeliger AU - Milan Speth AU - Jens Vogel-Claussen AU - Tobias Welte AU - Hendrik Suhling TI - Treatment with IL-5/IL-5R antibodies in patients with severe eosinophilic Asthma and COPD AID - 10.1183/23120541.00207-2022 DP - 2022 Jan 01 TA - ERJ Open Research PG - 00207-2022 4099 - http://openres.ersjournals.com/content/early/2022/09/01/23120541.00207-2022.short 4100 - http://openres.ersjournals.com/content/early/2022/09/01/23120541.00207-2022.full AB - Background Anti-eosinophilic therapy with interleukin-5/interleukin-5-receptor antibodies represents an established treatment for patients with severe eosinophilic asthma (SEA) but did not show clinical efficacy in patients with chronic obstructive pulmonary disease (COPD).Objective To evaluate treatment response to anti-eosinophilic antibody therapy in patients with Asthma and COPD.Methods A retrospective comparison of pulmonary function testing, oral corticosteroid intake, quality of life and pulmonary symptom control in patients with SEA and COPD and 1:1 propensity score matched patients suffering from SEA alone was performed. All patients received treatment with either mepolizumab or benralizumab. Data were assessed prior to antibody treatment start and after 6 months of therapy.Results Data from 84 patients (42 patients with SEA and COPD and 42 patients with SEA) were analysed. After 6 months of treatment, patients in both groups showed improved forced expiratory volume in one second (improvement by 11% [IQR 5; 18] in the SEA and COPD group versus 15% [IQR −3; 23]; p=0.637) and decreased oral corticosteroid dosages (median reduction by 3 mg in the SEA and COPD group versus 5 mg; p=0.070), without significant differences between groups. Pulmonary symptom control and quality of life improved in both groups. A significant decrease in eosinophils could be measured in both groups with similar cell numbers prior to treatment initiation (600 cells µL−1 in the SEA and COPD group versus 500 cells µL−1).Conclusion Anti-eosinophilic therapy with interleukin-5/interleukin-5-receptor antibodies shows clinical efficacy in patients with SEA and COPD comparable to treatment response in patients with SEA alone.FootnotesThis manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article.Conflict of interest: Nora Drick reports no conflict of interest.Conflict of interest: Jan Fuge reports personal fees/speaker honoraria from AstraZenecaConflict of interest: Benjamin Seeliger reports no conflict of interest.Conflict of interest: Milan Speth reports no conflict of interest.Conflict of interest: Jens Vogel-Claussen received grants advisory/lecture/clinical trial fees and non- financial support by BMBF (German Ministry of Research and Education), Siemens Healthineers, AstraZeneca, Bayer, Boehringer Ingelheim, GSK, MSD, Novartis, AstraZeneca, Coreline Soft all outside the submitted workConflict of interest: Tobias Welte T.W. and/or his institution received grants advisory/lecture/clinical trial fees and non- financial support by DFG (German Research Council), BMBF (German Ministry of Research and Education), BMG (German Ministry of Health), EU, WHO, AstraZeneca, Basilea, Biotest, Bayer, Boehringer, Berlin Chemie, GSK, Infectopharm, MSD, Novartis, Pfizer, Roche, AstraZeneca, Basilea, Biotest, Bayer, Boehringer, Gilead, GSK, Janssen, Novartis, Pfizer, Roche, all outside the submitted workConflict of interest: Hendrik Suhling reports personal fees/speaker honoraria from Astrazeneca, GSK, Novartis, Sanofi, outside the submitted work